Drug Therapy in Dyslipidemia

References

• The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36–69
   PubMed Web of Science ®Google Scholar
• Castelli W P. The triglycerides issue: A view from Framingham. Am Heart J 1989; 112(2)432–437
   Google Scholar
• Miller G J, Miller N E. Plasma high density lipoprotein concentration and development of ischaemic disease. Lancet 1975; 1: 16–19
   PubMed Web of Science ®Google Scholar
• Castelli W P, Doyle J T, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease: The cooperative lipoprotein phenotyping study. Circulation 1977; 55: 767–772
   PubMed Web of Science ®Google Scholar
• Keys A. Coronary heart disease in seven countries. Circulation 1970; 41: 11–1211
   Google Scholar
• Blackburn H. Diet and mass hyperlipidemia: Public health considerations - A point of view. Nutrition, Lipids, and Coronary Heart Disease, R Levy, B Rifkind, B Dennis, N Ernst. Raven Press, New York 1979; 309–348
   Google Scholar
• Grundy S M. Bile acid resins. Mechanisms of action, in Pharmacological Control of Hyper-lipidemia. S.A. J.R. Prous Science Publishers. 1986; 3–19
   Google Scholar
• Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351–364
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–374
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–381
   PubMed Web of Science ®Google Scholar
• Canner P L, Berge K G, Wenger N K, et al. Fifteen year mortality in Coronary Drug Project Patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–1255
   PubMed Web of Science ®Google Scholar
• Grundy S M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24–33
   PubMed Web of Science ®Google Scholar
• East C, Alivizatos P A, Grundy S M, Jones P H, Farmer J A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988; 318: 47–48
   PubMed Web of Science ®Google Scholar
• Norman D J, Illingworth D R, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988; 318: 46–47
   PubMed Web of Science ®Google Scholar
• Grundy S M, Vega G L. Fibric Acids: effects on lipids and lipoprotein metabolism. Am J Med 1987; 83: 9–20
   PubMed Web of Science ®Google Scholar
• Oliver M. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. B Heart J 1978; 40: 1069–1118
   PubMedGoogle Scholar
• Frick M H, Ole O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–1245
   PubMed Web of Science ®Google Scholar
• Kesaniemi Y A, Grundy S M. Influence of probucol on cholesterol and lipoprotein metabolism in man. J Lipid Res 1984; 25: 780–790
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Young S, Witzturn J L, Pittmann R C, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986; 77: 641–644
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenic ity. N Engl J Med 1989; 320: 915–923
   PubMed Web of Science ®Google Scholar
• Goldstein J L, Brown M S. Familial hypercholesterolemia in Stanbury. The Metabolic Basis of Inherited Disease, J B Wyngaarden, D S Fredrickson, J L Goldstein, M S Brown. McGraw-Hill, New York 1983; 672–713
   Google Scholar
• Kane J P, Malloy M L, Tun P, et al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 1981; 304: 251–258
   PubMed Web of Science ®Google Scholar
• Grundy S M, Vega G L, Bilheimer D W. Influence of combined therapy with mevinolin and interruption of bile- acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med 1985; 103: 339–343
   PubMedGoogle Scholar
• Vega G L, East C, Grundy S M. Effects of combined therapy with lovastatin and colestipol in heterozygous FH: Effects on kinetics of apolipoprotein B. Arteriosclerosis 1989; 9: I–135; I–144
   Google Scholar
• The Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in non-familial hypercholesterolemia: A multicenter study. JAMA 1986; 256: 2829–2834
   PubMed Web of Science ®Google Scholar
• Grundy S M, Vega G L. Causes of high blood cholesterol. Circulation 1989, In Press
   Google Scholar
• Grundy S M, Vega G L. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 1985; 26: 1464–1475
   PubMedGoogle Scholar
• Hoeg J M, Maher M B, Zech L A, et al. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am J Cardiol 1986; 57: 933–939
   PubMed Web of Science ®Google Scholar
• Vega G L, Grundy S M. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and cholesterol. JAMA 1987; 257: 33–38
   PubMed Web of Science ®Google Scholar
• Brown W V, Dujovne C A, Farquhar J W, et al. Effects of feno-fibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 1986; 6: 670–678
   PubMedGoogle Scholar
• Goldstein J L, Schrott H G, Hazzard W R, Bierman E L, Motulsky A G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544–1568
   PubMed Web of Science ®Google Scholar
• Brunzell J D, Schrott H G, Motulsky A G, Bierman E L. Myocardial infarction in familial forms of hypertriglyceridemia. Metabolism 1976; 25: 313–320
   PubMed Web of Science ®Google Scholar
• Kesaniemi Y A, Grundy S M. Dual defect in metabolism of very-low-density lipoprotein triglycerides. Patients with type 5 hyperlipoproteinemia. JAMA 1984; 251: 2542–2547
   Google Scholar